Detects equine IL‑6 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 50% cross-reactivity with recombinant human IL-6, recombinant porcine IL-6 and recombinant canine IL-6 is observed and approximately 20% cross-reactivity with recombinant mouse IL-6 and recombinant rat IL-6 is observed.
Polyclonal Goat IgG
E. coli-derived recombinant equine IL‑6 Phe26-Met208 Accession # Q95181
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Measured by its ability to neutralize IL‑6-induced proliferation in the T122.214.171.124 mouse plasmacytoma cell line. Nordan, R. P. and M. Potter (1986) Science 233:566. The Neutralization Dose (ND50) is typically 0.5-1.5 µg/mL in the presence of 4 ng/mL Recombinant Equine IL‑6.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Cell Proliferation Induced by IL‑6 and Neutralization by Equine IL‑6 Antibody.
Recombinant Equine IL‑6 (Catalog # 1886-EL) stimulates proliferation in the T1126.96.36.199 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Equine IL‑6 (4 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Equine IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1886). The ND50 is typically 0.5‑1.5 µg/mL.
IL‑6 in Equine PBMCs.
IL‑6 was detected in immersion fixed equine peripheral blood mononuclear cells (PBMCs) using Goat Anti-Equine IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1886) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to the cell surface. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is central to the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22 kDa‑28 kDa phosphorylated and variably glycosylated molecule (1‑4). Mature equine IL-6 is 181 amino acids (aa) in length and shares 61%, 42%, and 43% aa sequence identity with human, mouse, and rat IL-6 (5). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (6). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (7). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL‑6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 8).
Van Snick, J. (1990) Annu. Rev. Immunol. 8:253.
Hodge, D.R. et al. (2005) Eur. J. Cancer 41:2502.
Jones, S.A. (2005) J. Immunol. 175:3468.
Rose-John, S. et al. (2006) J. Leukoc. Biol. 80:227.
Swiderski, S.E. et al. Vet. Immunol. Immunopathol. 77:213.
Murakami, M. et al. (1993) Science 260:1808.
Muller-Newen, G. (2003) Sci. STKE 2003:PE40.
Mitsuyama, K. et al. (2006) Clin. Exp. Immunol. 143:125.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.